Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Semaglutide’s ability to help people lose weight is legend, but so is side effects. The active ingredient of Wagovi and Ozampic drugs, semaglutide is famous in some people for serious nausea, sometimes they stop treatment. However new research published in the journal Diabetes care Suggests that this effect may have an easy way to address.
Researchers, led by an Israeli team, found that the proposed 1 mg dose of the drug seems to be given more time and flexibility to low levels of nausea. Those who gradually followed the dose schedule also seemed less likely to stop using drugs, less than those who followed the more common methods. What’s more, the slow -moving group still lost weight almost like their peers.
Semaglotid GLP -1 works by duping, a hormone that plays a key role in controlling our metabolism and appetite. Since US regulators have approved the first drug for the treatment of diabetes, it has been very sought for hunger-aging and weight loss-but it has trade-offs. At least one -third of people feel nausea by adopting GLP -1 report, while others also experience constipation and gastrointestinal crisis.
People increase the dose of the drug, unpleasant GI effects can be worse before getting better. Generally, when people reach their proposed dose, they fade over time, but at least some people do not make it so far and only stop consuming drugs.
In the new test, researchers have divided 104 people into two groups with Type 2 diabetes: a set of semaglotted in a general, 8-week dosing program, the other group took up their dose slow, more flexible schedule. In the second group, even if they feel the signs of a GI and they were asked to extend their dose until they waited for them to feel better. Both groups were tracked for 24 weeks.
Overall, both groups saw similar improvements in their weight and blood sugar control. However, flexible users were less likely to have nausea than their peers (45.1% vs 64.2%), and nausea less days (2.88 vs 6.3 days per month). Perhaps most significantly, only 2% of the flexible patients have stopped taking the drug at the end of the study compared to 19%.
“Slowly, the flexible title has improved and reduced adverse events without functioning,” the writers of the study wrote.
Although some doctors have melodiously Report Similarly, the positive experience among their patients who switched to the slow schedule, the study of the study is limited: the size of the sample is quite small, and the larger and more diverse groups will need more work if different dosing schedules can help more people stay in their drugs, not getting pooks.